APA

Stainsby C. M., Perger T. M., Vannappagari V., Mounzer K. C., Hsu R. K., Henegar C. E., Oyee J., Urbaityte R., Lane C. E., Carter L. M., Pakes G. E. & Shaefer M. S. (20200220). Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure. : Pharmacotherapy.

Chicago

Stainsby Chris M, Perger Teodora M, Vannappagari Vani, Mounzer Karam C, Hsu Ricky K, Henegar Cassidy E, Oyee James, Urbaityte Rimgaile, Lane Charlotte E, Carter Lindsay M, Pakes Gary E and Shaefer Mark S. 20200220. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure. : Pharmacotherapy.

Harvard

Stainsby C. M., Perger T. M., Vannappagari V., Mounzer K. C., Hsu R. K., Henegar C. E., Oyee J., Urbaityte R., Lane C. E., Carter L. M., Pakes G. E. and Shaefer M. S. (20200220). Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure. : Pharmacotherapy.

MLA

Stainsby Chris M, Perger Teodora M, Vannappagari Vani, Mounzer Karam C, Hsu Ricky K, Henegar Cassidy E, Oyee James, Urbaityte Rimgaile, Lane Charlotte E, Carter Lindsay M, Pakes Gary E and Shaefer Mark S. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure. : Pharmacotherapy. 20200220.